Pyrrole-imidazole (PI) polyamides are novel gene silencers that strongly bind the promoter region of target genes in a sequence-specific manner to inhibit gene transcription. We developed a PI polyamide targeting human TGF-b1 (hTGF-b1). To develop PI polyamide targeting hTGF-b1 (Polyamide) as a practical medicine for progressive renal diseases, we examined the effects of Polyamide in two common marmoset models of nephropathy. We performed lead optimization of PI polyamides targeting hTGF-b1 by the dose-dependent inhibition of the PMA-stimulated expression of TGF-b1 mRNA in marmoset fibroblasts. Marmosets were housed with a 0.05% NaCl and magnesium diet and treated with cyclosporine A (CsA; 37.5 mg/kg/day, 8 weeks) to establish chronic nephropathy. Marmosets with nephropathy were treated with Polyamide (1 mg/kg/week, 4 weeks). We also established a unilateral urethral obstruction (UUO) model and examined the effects of Polyamide (1 mg/kg/week, 4 times) in marmosets. Histologically, the renal medulla from CsA-treated marmosets showed cast formation and interstitial fibrosis in the renal medulla.
Introduction
The academic field "chemical genomics" is a chemistry-based field that involves research on genomics associated with genetic diagnostics, genome drug discovery, biochips, biomaterials, and other related topics. Thus, chemical genomics are expected to be the most important field for next-generation drug-discovery. Middle molecule compounds (molecular weight 500-4,000), including peptide compounds, have received attention as next-generation medicines. Middle molecule compounds have great potential as multipoint interaction with target genes and proteins in comparison to small molecule compounds. Pyrrole-imidazole (PI) polyamides, a type of middle molecule peptide, were discovered based on chemical genomics.
PI polyamides are DNA recognized peptide compounds that were initially identified from antibiotics such as distamycin A and duocarmycin A. PI polyamides consist of aromatic rings of amino acids N-methylpyrrole and N-methylimidazole that recognize and bind to DNA with sequence specificity [1, 2] . Due to the ability of PI polyamides to form hydrogen bonds with high affinity and specificity to double stranded (ds)DNA, which is stronger in comparison to the bonds between protein and dsDNA. PI polyamides can inhibit protein interaction, including DNA transcription factors [3, 4] . The recognition of dsDNA depends upon the pairing of Pyrrole (Py) and Imidazole (Im) side-by-side in the minor groove. The pairing of Im opposite Py will target the G-C base pair, whereas Py-Im pairing will target the C-G base pair. Py-Py pairing targets A-T and T-A base pairs and causes degeneration [2] . Structural models of the bonding of synthetic polyamide to dsDNA are shown in Figure 1 . The synthetic polyamide was shown to bind to the appropriate B-form dsDNA in the minor groove [5] .
Transcriptional regulation is essential for genetic expression. The initiation of transcription requires the binding of transcription factors to the cognate DNA response elements in the gene promoter. Figure 2 shows a principle for the suppression of gene transcription. PI polyamides bind to the minor groove and the block binding of transcription factors inhibits genetic expression. PI polyamides designed to bind transcription factor binding sites can potentially suppress genetic expression.
PI polyamides are fully resistant to the biological degradation induced by nucleases. PI polyamides do not require vector-assisted delivery systems because of their cell permeability, and they may easily enter into nuclei. Thus, the applicability of PI polyamides as novel gene therapy agents might be greater than that of nucleic acid medicines [6] . Synthetic PI polyamides that can target gene promoters might therefore be effective as practical medicines for regulating gene transcription.
TGF-b represents a large family of cytokines that are involved in the regulation of growth, differentiation, and morphogenesis in a wide range of cell types [7] . TGF-β1
is a multifunctional cytokine that is associated with cell growth, matrix formation, tissue repair, and inflammation [8] . We previously reported that PI polyamides targeting human TGF-β1 (hTGF-β1) promoter significantly inhibit both the TGF-β1 promoter activity and the expression of TGF-β1 mRNA and protein in human cells [9] . We have demonstrated that a PI polyamide targeting TGF-β1 effectively attenuates progressive renal diseases [10, 11] , stenosis of the carotid artery after angioplasty [12] , alkali burn of the cornea [13] , skin hypertrophic scar [14] , liver fibrosis [15] and encapsulating peritoneal sclerosis [16] in rats.
Despite the availability of long-term therapies, progressive renal diseases caused by diabetic nephropathy, chronic glomerulonephritis and glomerulosclerosis cannot be cured through current treatments. Two hundred eighty thousand patients with end-stage renal failure undergo dialysis, and 37,000 patients newly receive dialysis every year in Japan. The medical expenses associated with dialysis represent a large problem for the medical economy. Thus, the development of a definitive treatment for chronic renal failure is a pressing issue. The PI polyamide targeting hTGF-b1 is a candidate compound as a definitive medicine for the treatment of progressive renal diseases.
In order to determine a lead compound among PI polyamides targeting human TGF-b1, we designed 7 PI polyamides to bind the hTGF-b1 promoter sequences [17] .
We chose a lead compound based on the effects of these 7 PI polyamides on the hTGF-b1 mRNA expression in human vascular smooth muscle. We demonstrated that a relatively low dose of the lead compound completely inhibited the hypertrophic scar on the skin of common marmosets [18] .
In the current preclinical study, we examined the effects of a PI polyamide targeting hTGF-b1 on the progression of renal injury in common marmosets in order to evaluate PI polyamides as practical medicines for the treatment of progressive renal diseases in humans.
Results
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Effects of Polyamide on fibrosis in CsA-induced nephropathy in marmosets

Effects of Polyamide on the expression of TGF-b1 in
Effects of Polyamide on the expression of TGF-b1 and Snail mRNAs in marmoset
kidneys with UUO Figure 8 shows expression of TGF-b1 and Snail mRNAs in the renal medulla the from CUK and UUO kidneys in marmosets. The abundance of TGF-b1 (p < 0.01) and Snail (p < 0.05) mRNAs was significantly higher in the renal medulla of the UUO kidney in comparison to the renal medulla of the CUK kidney. After Polyamide treatment, the abundance of TGF-β1 and Snail mRNAs was significantly (p < 0.01) decreased in the UUO kidney in comparison to the untreated UUO kidney.
Discussion
In this study, we created two types of nephropathy in common marmosets: CsA-induced nephropathy and UUO nephropathy. It has been reported that CsA induces acute and chronic nephropathies. The acute nephropathy is reversible and induced by the contraction of afferent arterioles with an increase in intracellular calcium ion, increased endothelial damage due to the release of endothelin, and decreases in vasodilated prostaglandin E2 and I2 and nitric oxides [19] . The chronic administration of CsA mainly induces nephrotubular injury through increases in TGF-b1, and is associated with arteriole degeneration, focal glomerulosclerosis, and interstitial fibrosis due to hyperfiltration with a decreased number of nephrons [20, 21] . These histopathological changes in CsA-induced nephropathy are known to be enhanced with lower blood levels of magnesium and sodium [22] . In this study, we therefore created a CsA-induced nephropathy in common marmosets fed a low sodium and magnesium diet. On the other hand, the spontaneous onset of nephropathy, such as the IgA nephropathy named
Wasting marmoset syndrome, has been reported in individual common marmosets showing variable kidney degeneration [23] . In this study, Polyamide (1 mg/kg/week, for 5 weeks) effectively improved the CsA-induced renal fibrosis and completely inhibited TGF-b1 staining in the marmoset renal medulla.
We next investigated the effects of a PI polyamide targeting hTGF-b1 in marmoset kidneys with UUO, which is a standard model of renal fibrosis. In the UUO kidney, histological changes and immunostaining of target molecules can be compared to CUK kidney in the same animal. In the UUO kidney, renal tubules stimulates the production of TGF-b1, which induces the epithelial-mesenchymal transition (EMT) of the renal tubules and interstitial fibrosis [24, 25] . In the present study, treatment with the PI polyamide targeting hTGF-b1 significantly suppressed the fibrosis of the renal medulla, with decreases in immunostaining of TGF-β1 and a-SMA, increased
immunostaining of E-cadherin, and inhibited the expression of TGF-b1 and Snail mRNAs in marmoset kidneys with UUO. These findings indicate that PI polyamide targeting human TGF-b1 effectively suppress renal fibrosis and the EMT phenomenon in renal tubules in human nephropathies and that PI polyamide targeting human TGF-b1
has the potential to be developed as a practical medicine for human glomerulonephritis.
To evaluate the characteristics of PI polyamides as practical medicines, we investigated their pharmacokinetics, including the binding of PI polyamides to nuclei and chromosomes. FITC-labeled PIpolyamide strongly localized to the nuclei in the renal tubules andglomeruli at 24 hours after injection in rats. The PI polyamidewas also localized to the nucleiin the mid-layer smooth muscle of the aorta, lung and liver without any drug delivery system (DDS). An HPLC analysis of FITC-labeled PI polyamide also showed that PI polyamide was clearly detected in the urine, kidney and aorta, but not in the heart or brain [10] . Thus, PI polyamides themselves can be delivered to the organs and strongly bind to the nucleus, which is a potential advantage in comparison to nucleic acid medicines, such as siRNA and antisense DNA, which require certain DDSs. After the intravenous administration of FITC-labeled PI 8 polyamides in rats, PI polyamides remained in the nuclei of the renal tubules on day 14, indicating that the "once a week" administration of PI polyamides may be effective for the treatment of progressive renal diseases [11] . In addition, we examined the binding of PI polyamide in chromosomal DNA. The binding pattern of the PI polyamide in the chromosomal DNA in HeLa cells was obviously different from the DAPI on the chromosome, indicating that the PI polyamides bind to the chromosome in a sequence-specific manner [11] . We then analyzed the pharmacokinetics of the PI polyamide. The pharmacokinetic parameters of PI polyamides are linear in the intravenous dose ranges, as revealed by the fact that the area under the blood concentration time curve (AUC) increased linearly as a function of the dose [26] . PI polyamides were mainly excreted in the urine, and low molecular weight PI polyamide was partially excreted in bile [27] .
We performed a safety study of PI polyamides to investigate the lethal dose and side effects. The lethal doses of the polyamide were >40 mg/kg, and doses of <20 mg/kg were considered safe. Furthermore, PI polyamides did not show obvious side effects in mice. At 5 days after the injection of PI polyamide (20 mg/kg), there were no abnormalities in the serological data (e.g., blood cell counts, liver enzyme levels, total protein and lipid profiles). Next, we investigated the long-termeffects of the 4-week administration of PIpolyamide (1 mg/kg) on TGF-b1 in Dahl S-rats. Body weightand food consumption were not affected by the long-termadministration of PI polyamide.
Thus, these data indicate that the systemic administration of PI polyamides was not associated with any systemic side effects [11] .
For the drug-discovery of DNA-recognized medicines, such as siRNA, antisense DNA and PI polyamides, off-target effects caused by binding to other genes and suppressing the function of non-target genes represent a large problem. To confirm the specificity of PI polyamides targeting the TGF-b1 promoter, we previously performed a microarray analysis of the kidney in Dahl-S rats treated with PI polyamide targeting TGF-b1 [11] . In the analysis, the PI polyamide affected only 3% of the 430,000 interrogated kidney transcripts from Dahl-S rats. We performed a further analysis of the promoter structure in these inhibited genes for the presence of AP-1 sites and PI polyamide-binding sites. There were only a few common sites of AP-1 and PI polyamide binding in the 3 kb upstream of the transcription initiation sites in these inhibited genes, which were all TGF-b1-related molecules. We therefore assumed that the PI polyamide particularly suppressed the TGF-b1 gene at the transcription level because we designed a PI polyamide spanning the transcription binding sequences and target gene-specific sequences. These findings indicate the high specificity of PI polyamide to the target gene.
Recently some groups have developed alkylating PI polyamides as anticancer agents [28] [29] [30] . DNA alkylating agents can damage cellular DNA and lead to anticancer activity. Since the non-specific DNA alkylation damages normal cells, alkylating PI polyamides can damage cancer cells in sequence-specific alkylation for cancer genes [31] . However, the off-target effects of the alkylating PI polyamides by binding and In conclusion, in the present study we examined the effects of low-dose treatment with a PI polyamide targeting hTGF-b1 that was injected once a day in common marmoset models of chronic nephropathy induced by CsA and UUO, as a preclinical study. The synthetic PI polyamide targeting hTGF-b1 effectively improved nephropathy in common marmosets. These results indicate that the PI polyamide will be developed as a medicine that may provide a radical cure for progressive renal diseases. successive washes of the resin were performed with methanol. The coupling step was carried out with Fmoc-amino acid, followed by a methanol wash. We repeated these steps until the entire sequencing was complete. After completion of the coupling steps, the N-terminal amino group was protected and washed with DMF, then the reaction vessel was drained. We next isolated the synthetic polyamides after the cleavage step (5 ml of 91% trifluoroacetic acid-3% triisopropylsilane-3% 5 dimethylsulfide-3% water/0.1 mmol resin) by cold ethyl ether precipitation. The synthetic polyamides were isolated after the cleavage step (5 ml of N, N-dimethylaminopropylamine/0.1 mmol resin, 50°C overnight) by cold ethyl ether precipitation. To purify the polyamides, high-performance liquid chromatography (HPLC) was performed using a PU-980 HPLC pump, a UV-975 HPLC UV/VIS detector (Jasco, Easton, MD), and a Chemcobound 5-ODS-H column (Chemco Scientific, Osaka, Japan).
Materials and Methods
Design and synthesis of PI polyamides to hTGF-β1 promoter
Cell culture
Marmoset fibroblasts were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, CA) and 50 mg/ml streptomycin (Invitrogen). After it reached confluence (7-10 days after seeding 1 vial of 10 5 cells/cm 2 ), the VSMC culture displayed a typical hill-and-valley pattern.
Marmoset fibroblasts were prepared from newborn skin by digestion with 5 mg/ml collagenase type I (Sigma, St. Louis, MO) overnight. They were cultured in DMEM supplemented with 10% fetal calf serum, 0.1 mg/ml penicillin and 0.05 mg/ml gentamicin. Cells were passaged by trypsinization with 0.05% trypsin (Gibco Life Technologies, Gaithersburg, MD) and plated in 6-or 24-well culture dishes at a density of 10 5 cells/cm 2 . Cells were cultured in a water-saturated CO2 incubator at 37°C.
RNA extraction and real-time PCR
TRIzol reagent (Invitrogen, CA) was used to extract total RNA from cultured cells. The total RNA (1 µg) was then reverse transcribed into cDNA with random 9-mers with a Takara RNA PCR Kit (AMV) Ver. 3.0 (Takara Bio, Ohtsu, Japan).
Assay-on-Demand primers and probes (human TGF-β1: Hs00998133_m1) were 
Ethics
This study conformed to the standards of the US National Institute of Health's (Duphasol AE3D; Kyoritsu Seiyaku Co., Ltd., Tokyo, Japan), and honey (Nihonhatimitsu Co., Ltd., Gifu, Japan). The marmosets were fed with chow moistened with hot water in the morning and dry chow in the afternoon. In addition to the normal diet, the marmosets were fed with sponge cakes, biscuits or apple jelly when in contact with humans. Each of the cages contained puzzle feeders. The had ad libitum access to tap water from feed valves. No marmosets were sacrificed for the experiments involving skin hypertrophic scar creation.
Guide for the Care and Use of Laboratory Animals
Creation of nephropathy in marmosets and treatment with PI polyamides
We created two types of nephropathy in marmosets. Male marmosets weighing 300 to 350 g were housed with a 0.05% NaCl and 0.05% magnesium diet and were subcutaneously injected with 40 mg/kg/day cyclosporine A (CsA, Novartis Pharmaceuticals, Basel, Switzerland) for 8 weeks to establish chronic nephropathy. 
Histopathological and immunohistochemical examinations
Tissue samples from the kidney were fixed in 10% neutral buffered formalin solution and embedded in paraffin. Sections of 4 µm in thickness were then stained with 
Statistical Analysis
Values are shown as the mean ± SE. We used Student's t-test for to analyze unpaired data and a two-way ANOVA with the Bonferroni/Dunn procedure as a post hoc test. P values of < 0.05 were considered to indicate statistical significance.
Conclusions
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The synthetic PI polyamide targeting hTGF-b1 effectively improved nephropathy induced by CsA and UUO in common marmosets as preclinical study. These results indicate that the PI polyamide can be developed as a practical medicine for progressive renal diseases. 
